PHA 2024

The Pulmonary Hypertension Association's biennial conference brings together more than 1,300 people with pulmonary hypertension, caregivers and health care professionals. The conference focuses on the latest research and treatments, ways to thrive with PH, and opportunities to participate in research and connect with others in the PH community. The theme for this year's conference is "Stronger Together." 

Online registration is now closed, you may still register onsite.  

 


Conference Agenda     Scientific Sessions Agenda 

Featured Sessions

PHA/PVRI Joint Session: The Real-World Evidence in PAH
 

Description: 
Traditional randomized clinical trials are  powerful tools for developing scientific evidence about therapeutic interventions. RCTs guide regulatory approval of new drugs and devices, and are the foundation of clinical guidelines. Yet, RCTs recruit highly selected populations and manage them in controlled settings, which makes it difficult to generalize the results to broader, diverse populations seen  in clinical practice. Clinicians, regulators, payers and the pharmaceutical industry increasingly recognize the use of real‐world evidence to complement to knowledge gained from RCTs. During this session, the presenters will discuss the meaning of RWE in the context of pulmonary arterial hypertension, as well as  regulatory requirements for therapy approval based on  real-world evidence.

Featured Presenters:

Jean Elwing, MD, FCCP

Elwing Photo

Kari R. Gillmeyer, MD, MSc

Gillmeyer Photo

Sandeep Sahay, MD, MSc

Sahay Photo

Greg Elliott, MD, MACP
(co-moderator)

Elliott Photo

Teresa De Marco, MD, FACC, FHFSA 
(co-moderator)

DeMarco Photo

 

Changing the Paradigm in Treating Patients with Pulmonary Hypertension and Parenchymal Lung Disease
 

Description: Pulmonary hypertension, which often occurs alongside parenchymal lung disease, significantly worsens the prognosis compared to having either condition alone. In this session, speakers will explore interstitial lung disease, chronic obstructive pulmonary disease and pediatric lung disease-associated pulmonary hypertension. The session will include a discussion of prior studies of pulmonary vasodilators; methods to identify patients with ILD and COPD who may respond to systemic pulmonary vasodilators; the success of the INCREASE trial and how to optimize the use of inhaled treprostinil. The session also will address future directions in studying this complex condition and unique challenges associated with  pediatric patients.

Featured Presenters:

Nicholas Kolaitis, MD, MAS

Kolaitis Photo

Oksana Shlobin, MD

Shlobin Photo

Jordin Rice, RN, BSN

Rice Photo

Maidah Yaqoob, MD

Yaqoob Photo

Yuri Matusov, MD, FACP
(co-moderator)

Matusov Photo

Oisin O’Corragain, MD
(co-moderator)

O'Carragain Photo


 

PHA2024 Stronger Together

Programs and Activities

Learn more about PHA 2024 programs and activities:

 

 

 


Travel and Safety

JW  Marriott

Hotel Information

JW Marriott Indianapolis
10 S West St 
Indianapolis, IN 46204

Click here for information about planning your trip to Indianapolis.
 

 

 


PHA 2024 Conference Committee

Nicole Creech, Patient: Co-Chair, 
Traci Stewart, RN: Co-Chair
Diane Brakin, MSN, APRN, AGNP-C
Nancy Elena Rivas Elizondo, Caregiver
Rachel Hopper, MD
Jessie Kohler, JD, Patient 
Fran Rogers, CRNP